Levetiracetam for Benign Rolandic Epilepsy

Johns Hopkins University6 enrolled

Overview

This study is designed to test if the language problems commonly seen in children with benign rolandic epilepsy would improve by switching anticonvulsants to levetiracetam.

This is a 6 month study in which children on another anticonvulsant would have EEG, language testing, and a clinic visit at baseline. They would then be rapidly transitioned off of their current anticonvulsant and onto levetiracetam (Keppra). Repeat EEG and language testing would be done after 6 months to evaluate for improvement.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Epilepsy

Interventions

LevetiracetamDRUG

Eligibility

Sex: ALLMin age: 6 YearsMax age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Ages 6-12 * Benign rolandic epilepsy * Language difficulties as reported by parents or teachers * On another anticonvulsant other than levetiracetam Exclusion Criteria: * Prior use of levetiracetam * On 2 or more anticonvulsants * Language problems prior to epilepsy * Another seizure disorder * Status epilepticus within the past 6 months * Significant psychiatric disease * Progressive neurologic disease

Locations (1)

Johns Hopkins Hospital

Baltimore, Maryland, United States

Outcomes

Primary Outcomes

Language improvement

Secondary Outcomes

Seizure control

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.